Search clinical trials for: MK2295

Total 41 results

Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety and Efficacy of an Investigational Drug in the Treatment of Postoperative Dental Pain (MK-2295-005)

Pain, Postoperative | Tooth Extraction
Merck Sharp & Dohme LLC

Completed

A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007)

Solid Tumors
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Squamous Cell Carcinoma of the Nasopharynx | Stage IV Squamous Cell Carcinoma of the Nasopharynx

United States, Singapore, China
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Recurrent Gastric Carcinoma | Adenocarcinoma of the Gastroesophageal Junction | Diffuse Gastric Adenocarcinoma | Gastric Intestinal Type Adenocarcinoma | Gastric Mixed Adenocarcinoma

United States, Canada
Merck Sharp & Dohme LLC

Terminated

A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

Type 2 Diabetes Mellitus
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Cancer AJCC v7 | Stage IVB Major Salivary Gland Cancer AJCC v7 | Stage IVC Major Salivary Gland Cancer AJCC v7 | Salivary Gland Adenoid Cystic Carcinoma | Recurrent Oral Cavity Adenoid Cystic Carcinoma | Stage IVA Oral Cavity... and other conditions

United States
National Cancer Institute (NCI)

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic... and other conditions

United States
Centre Leon Berard
National Cancer Institute, France

Terminated

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (AKTIL)

Diffuse Large B Cell Lymphoma

France
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer

United States
National Cancer Institute (NCI)

Completed

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Stage IV Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder...

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Adenocarcinoma | Endometrial Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Completed

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
National Cancer Institute (NCI)

Completed

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Sarcoma

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B Cell Lymphoma

France
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditions

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED)

Type 2 Diabetes
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Kaleido Biosciences

Completed

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

Ulcerative Colitis

Ireland, United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal... and other conditions

United States
National Taiwan University Hospital

Unknown

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

Taiwan
National Cancer Institute (NCI)

Completed

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States, Canada
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
National Cancer Institute (NCI)

Active, not recruiting

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma... and other conditions

United States
A.P.J. Vlaar
Maastricht University Medical Center; Maastricht University; Matisse Pharmaceuticals

Completed

Intravenously Administered M6229 in Critically Ill Sepsis Patients (HistoSeps)

Sepsis | Critical Illness | Septic Shock

Netherlands
National Cancer Institute (NCI)

Withdrawn

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Cancer | Stage II Gallbladder Cancer | Stage IIIA Gallbladder Cancer | Stage IIIB Gallbladder... and other conditions
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Completed

MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Adenosquamous Lung Carcinoma | Bronchioloalveolar Carcinoma | Large Cell Lung Carcinoma | Squamous Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer

United States
University Medical Center Groningen

Recruiting

[18F]MC225-PET in Neurodegenerative Disease

Parkinson Disease | Neurodegenerative Diseases | Alzheimer Disease | Mild Cognitive Impairment

Netherlands
University Medical Center Groningen

Not yet recruiting

[18F]MC225 PET to Evaluate Gender Differences in BBB P-gp Function

Gender
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIC Breast Cancer | Adenocarcinoma of the Gastroesophageal Junction | Recurrent Breast Cancer | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage IIIC Gastric... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Carcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage III Prostate Cancer AJCC v7 | Stage I Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States, Ireland
National Cancer Institute (NCI)

Completed

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Recurrent Breast Carcinoma | Invasive Breast Carcinoma | Estrogen Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7

United States
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative

United States
National Cancer Institute (NCI)

Completed

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Adult Solid Neoplasm

United States
Sheba Medical Center

Withdrawn

The Effectiveness of Idazoxan in Treating TRD

Major Depressive Disorder

Israel
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (S1115)

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
King Saud University

Completed

Prophylaxis for Aspiration of Gastric Contents.

Pulmonary Aspiration of Gastric Contents

Search clinical trials for: MK2295

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations